SYSTEMATIC REVIEW OF OUTCOMES AFTER GEL STENT SURGERY

A new peer-reviewed paper is available from *Clinical Ophthalmology*.

WHO ARE THE AUTHORS?

Joseph F. Panarelli, MD
Department of Ophthalmology, New York University, New York

Vanessa Vera, MD
Allergan, an AbbVie Company, Dublin

Arsham Sheybani, MD
Department of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis

Nathan Radcliffe, MD
Department of Ophthalmology, New York Eye and Ear Infirmary, New York

Richard Fiscella, PharmD, MPH
Allergan, an AbbVie Company, Dublin

Brian A. Francis, MD
Department of Ophthalmology, Doheny Eye Institute, University of California Los Angeles, Los Angeles

Oluwatosin U. Smith, MD
Glaucoma Associates of Texas, Dallas

Robert J. Noecker, MD
Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut & Ophthalmic Consultants of Connecticut, Fairfield, Connecticut

What is the most likely IOP response following successful implantation of a gel stent (Allergan, an AbbVie Company)? What patient characteristics are most likely to predict a response with the implant?

The ophthalmologist treating patients with glaucoma faces many questions when deciding whether and how to intervene. Published studies can be a guide to understanding how a particular device or surgery will perform in certain settings. Yet, since it was developed, the gel stent has been subjected to over 100 separate clinical and observational studies, conducted in all manner of formats and designs. How, then, can the busy ophthalmologist stay current on most likely outcomes so they can have fruitful conversations with patients?

Recognizing an opportunity to compile a resource to aid in clinical decision-making, a prominent group of glaucoma experts (see *Who Are the Authors?*) recently reviewed outcomes from 111 studies to determine the most likely IOP response and medication reduction after surgery. In the new paper from *Clinical Ophthalmology*, "Intraocular Pressure and Medication Changes Associated with Gel Stent: A Systematic Review of the Literature," the authors demonstrate a postoperative IOP of around 14.0 mm Hg with use of fewer than 1 glaucoma medication in various analyses, including prospective and retrospective settings, at 12, 24, and 36 months, even when baseline factors are considered.[1]

Scan the QR code below to read this comprehensive resource of effectiveness outcomes associated with gel stent surgery. ■

1. Panarelli JF, Vera V, Sheybani A, et al. Intraocular pressure and medication changes associated with gel stent: a systematic review of the literature. *Clin Ophthalmol*. 2023;17:25-46.


Clinical Ophthalmology Dovepress

REVIEW

Intraocular Pressure and Medication Changes Associated with Xen Gel Stent: A Systematic Review of the Literature

Introduction